Mutation of herpesvirus thymidine kinase to generate ganciclovir-specific kinases for use in cancer gene therapies.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Protein Engineering

• Publication date

  2002-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/PROTEIN/15.11.903PMID 12538910
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ganciclovir

  2012cited by this paper
• Optimizing Prostate Cancer Suicide Gene Therapy Using Herpes Simplex Virus Thymidine Kinase Active Site Variants

  2002cited by this paper
• T cell transduction and suicide with an enhanced mutant thymidine kinase

  2002cited by this paper
• Cytogenetic genotoxicity of anti-herpes purine nucleoside analogues in CHO cells expressing the thymidine kinase gene of herpes simplex virus type 1: comparison of ganciclovir, penciclovir and aciclovir.

  2000cited by this paper
• Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: Implications for gene therapeutic approaches

  2000cited by this paper
• Conservative mutations of glutamine-125 in herpes simplex virus type 1 thymidine kinase result in a ganciclovir kinase with minimal deoxypyrimidine kinase activities.

  2000influential reference
• Differential Ganciclovir-mediated Cell Killing by Glutamine 125 Mutants of Herpes Simplex Virus Type 1 Thymidine Kinase*

  1999influential reference
• Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant

  1999influential reference
• Irreversible G2-M arrest and cytoskeletal reorganization induced by cytotoxic nucleoside analogues.

  1998cited by this paper
• A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma.

  1998cited by this paper
• S- and G2-phase cell cycle arrests and apoptosis induced by ganciclovir in murine melanoma cells transduced with herpes simplex virus thymidine kinase.

  1998cited by this paper
• Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy in Patients with Localized Malignancy: Results of a Phase I Clinical Trial in Malignant Mesothelioma

  1998cited by this paper
• Exploring the active site of herpes simplex virus type‐1 thymidine kinase by X‐ray crystallography of complexes with aciclovir and other ligands

  1998influential reference
• Differential Ganciclovir-Mediated Cytotoxicity and Bystander Killing in Human Colon Carcinoma Cell Lines Expressing Herpes Simplex Virus Thymidine Kinase

  1998cited by this paper
• A Phase I/II Dose-Escalation Study of Herpes Simplex Virus Type 1 Thymidine Kinase “Suicide” Gene Therapy for Metastatic Melanoma

  1998cited by this paper
• Superior cytotoxicity with ganciclovir compared with acyclovir and 1-beta-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing.

  1998cited by this paper
• Random sequence mutagenesis for the generation of active enzymes.

  1996cited by this paper
• Proteolytic mapping of the thymidine/thymidylate binding site of herpes simplex virus type 1 thymidine kinase: a general photoaffinity labeling method for identifying active-site peptides.

  1996cited by this paper
• Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.

  1996influential reference
• In situ use of suicide genes for cancer therapy.

  1996cited by this paper
• Purification and Photoaffinity Labeling of Herpes Simplex Virus Type-1 Thymidine Kinase (*)

  1995influential reference
• Crystal structures of the thymidine kinase from herpes simplex virus type-I in complex with deoxythymidine and Ganciclovir

  1995influential reference
• Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

  1994cited by this paper
• Site-directed mutagenesis clarifies the substrate position within the three-dimensional model of the active site of herpes simplex virus type-1 thymidine kinase.

  1994cited by this paper
• Permissible amino acid substitutions within the putative nucleoside binding site of herpes simplex virus type 1 encoded thymidine kinase established by random sequence mutagenesis [corrected].

  1992cited by this paper
• Mutagenesis.

  1990cited by this paper
• Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: effects on catalytic activity.

  1988cited by this paper
• Comparison of susceptibilities of varicella-zoster virus and herpes simplex viruses to nucleoside analogs

  1986cited by this paper
• Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide.

  1986cited by this paper
• Properties of purified enzymes induced by pathogenic drug-resistant mutants of herpes simplex virus. Evidence for virus variants expressing normal DNA polymerase and altered thymidine kinase.

  1983cited by this paper
• Kinetic studies of herpes simplex virus type 1-encoded thymidine and thymidylate kinase, a multifunctional enzyme.

  1979cited by this paper
• Association of thymidylate kinase activity with pyrimidine deoxyribonucleoside kinase induced by herpes simplex virus.

  1978cited by this paper
• Virology

  1955cited by this paper

• Recombinant Enzymes in the Food and Pharmaceutical Industries

  2019cites this paper
• Thymidine kinase and protein kinase in drug-resistant herpesviruses: Heads of a Lernaean Hydra.

  2018cites this paper
• Intermedilysin-mediated cell ablation in the rat and zebrafish

  2016cites this paper
• Bifidobacterial recombinant thymidine kinase-ganciclovir gene therapy system induces FasL and TNFR2 mediated antitumor apoptosis in solid tumors

  2016influential citation
• A designed equine herpes thymidine kinase (EHV4 TK) variant improves ganciclovir-induced cell-killing.

  2014cites this paper
• Digital switching in a biosensor circuit via programmable timing of gene availability

  2014cites this paper
• Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy.

  2012cites this paper
• Recent Advances and Improvements in the Biosafety of Gene Therapy

  2011cites this paper
• Gene Therapy - Developments and Future Perspectives

  2011cites this paper
• Plant thymidine kinase 1: a novel efficient suicide gene for malignant glioma therapy.

  2010cites this paper
• Comparative analysis of herpes simplex virus thymidine kinase gene expression potentiation via HIV-1 Tat-TAR system and cancer-specific promoters in P53(+) and P53(-) cells

  2010cites this paper
• TK.007: A Novel, Codon-Optimized HSVtk(A168H) Mutant for Suicide Gene Therapy

  2010cites this paper
• EVALUATION OF THERMOSTABLE YEAST CYTOSINE DEAMINASE AND HERPES SIMPLEX VIRUS THYMIDINE KINASE FUSIONS IN DOUBLE SUICIDE GENE THERAPY FOR CANCER

  2009cites this paper
• Engineering Kinases to Phosphorylate Nucleoside Analogs for Antiviral and Cancer Therapy.

  2009cites this paper
• The role of herpes simplex virus-1 thymidine kinase alanine 168 in substrate specificity.

  2008cites this paper
• Neural stem cell-mediated enhanced gene therapy of malignant gliomas using a novel plant thymidine kinase

  2008cites this paper
• Development and validation of a capillary electrophoresis method for the characterization of herpes simplex virus type 1 (HSV-1) thymidine kinase substrates and inhibitors.

  2007cites this paper
• Directed evolution for drug and nucleic acid delivery.

  2007cites this paper
• Enhancement of HSV-TK / GCV suicide gene therapy of cancer

  2006cites this paper
• Engineering of a Single Conserved Amino Acid Residue of Herpes Simplex Virus Type 1 Thymidine Kinase Allows a Predominant Shift from Pyrimidine to Purine Nucleoside Phosphorylation*

  2006cites this paper
• Investigation of antiviral and anticancer nucleoside analog substrate recognition of drosophila melanogaster and herpes virus deoxyribonucleoside kinases

  2006cites this paper
• Engineering enhanced enzymes for suicide gene therapy of cancer

  2006cites this paper
• Direct evidence for the absence of intercellular trafficking of VP22 fused to GFP or to the herpes simplex virus thymidine kinase

  2005cites this paper